[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"First Affiliated Hospital of Fujian Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":625},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,38,0,25,[9,47,71,95,121,144,169,197,219,245,266,284,307,331,364,385,409,427,455,476,496,519,550,577,596],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100643453","preventive-narrative-exposure-intervention-for-ptsd-in-icu-patients-after-cardiopulmonary-bypass-cardiac-surgery-100643453",false,"NCT07632131","Preventive Narrative Exposure Intervention for PTSD in ICU Patients After Cardiopulmonary Bypass Cardiac Surgery","Effects of Preventive Narrative Exposure Intervention on Posttraumatic Stress Disorder Among ICU Patients After Cardiopulmonary Bypass Cardiac Surgery: A Randomized Controlled Trial","ICU-pNET","Inclusion Criteria:\n\n1. Aged 18 years or older.\n2. Scheduled to undergo cardiac surgery with cardiopulmonary bypass, with planned postoperative admission to the cardiac surgical intensive care unit and an expected ICU stay of more than 24 hours.\n3. The participant is able to communicate effectively, and the participant and family members are willing to cooperate with the study.\n4. Conscious before the first postoperative intervention, negative for delirium as assessed by the Confusion Assessment Method for the Intensive Care Unit, and able to understand and complete the intervention and related assessments.\n\nExclusion Criteria:\n\n1. Experienced severe traumatic events within the past year, such as diagnosis of a major disease unrelated to the current cardiac condition in the participant or an immediate family member, or death of an immediate family member or significant other.\n2. Currently receiving treatment for mental disorders, including pharmacological treatment or psychotherapy for conditions such as depressive disorder, anxiety disorder, bipolar disorder, or schizophrenia spectrum disorders.\n3. History of a clearly diagnosed severe mental disorder, or mental abnormalities caused by organic brain disease.","ALL","18 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical trial aims to evaluate whether an ICU-based preventive narrative exposure intervention can help prevent posttraumatic stress symptoms in adult patients after cardiac surgery with cardiopulmonary bypass.\n\nThe study will include adult patients who undergo cardiac surgery with cardiopulmonary bypass and are admitted to the cardiac surgical intensive care unit. Participants will be randomly assigned to either the intervention group or the control group.\n\nParticipants in the control group will receive routine care and routine psychological support. Participants in the intervention group will receive routine care plus an ICU-based preventive narrative exposure intervention supported by an ICU visitor book. The intervention includes preoperative education, review of ICU experiences, construction of a timeline, guided narration of stressful ICU-related events, and integration of the experience before discharge.\n\nThe ICU visitor book includes selected photos, family messages, and key recovery events. It is used to help patients better understand and organize their ICU experience.\n\nResearchers will compare the intervention group with the control group to see whether the intervention reduces posttraumatic stress symptoms. The primary outcome is posttraumatic stress symptoms at 1 month after discharge. Secondary outcomes include posttraumatic stress symptoms at 3 months after discharge, ICU memories, anxiety, depression, sleep quality, quality of life, and patient and family satisfaction with ICU care.\n\nThe findings may provide evidence for an early psychological nursing intervention to prevent posttraumatic stress disorder in ICU patients after cardiopulmonary bypass cardiac surgery.",[28,29,30],"Cardiopulmonary Bypass","Intensive Care Units","Stress Disorders, Post-Traumatic",[28,32,33,30],"Intensive Care Unit","Narrative Exposure","RECRUITING","2026-06-03",{"date":37,"type":38},"2026-06-08","ACTUAL",{"date":40,"type":38},"2026-06-02",{"date":42,"type":22},"2027-04-30",{"name":44,"class":45},"First Affiliated Hospital of Fujian Medical University","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100638586","predicting-bph-surgery-outcomes-using-a-preoperative-scoring-system-100638586","NCT07623239","Predicting BPH Surgery Outcomes Using a Preoperative Scoring System","Development and Clinical Application Value of a Predictive Scoring System for Postoperative Outcomes Following Transurethral Resection of the Prostate Based on Preoperative Multidimensional Objective Indicators","Inclusion Criteria:\n\n* \\- Postoperative pathological diagnosis of benign prostatic hyperplasia (BPH)\n* Completion of pelvic or prostate magnetic resonance imaging (MRI) plain scan within 1 month before surgery\n* Completion of urodynamic study within 1 month before surgery\n* Completion of International Prostate Symptom Score (IPSS) both before and after surgery\n* Complete and retrievable clinical and pathological data\n* Generally good condition without infection, autoimmune disease, hematologic disease, or other malignancies\n* Complete follow-up data with follow-up duration of at least 6 months after surgery\n\nExclusion Criteria:\n\n* \\- Concomitant prostate cancer or other malignancies\n* Prior prostate surgery or pelvic radiotherapy\n* Severe cardiac, pulmonary, hepatic, or renal insufficiency precluding tolerance of surgery\n* Intraoperative or postoperative severe complications affecting efficacy assessment\n* Follow-up duration less than 6 months or missing key data\n* Poor patient compliance precluding completion of necessary assessments and follow-up\n* Incomplete clinical, imaging, urodynamic, or pathological data, or loss to follow-up","MALE","30 Years","100 Years",{"count":58,"type":22},2000,"OBSERVATIONAL","This study aims to develop and validate a preoperative predictive scoring system for surgical outcomes in patients with benign prostatic hyperplasia (BPH) undergoing prostate surgery (including but not limited to transurethral resection of the prostate, laser enucleation, photoselective vaporization, or robot-assisted simple prostatectomy).\n\nIt is a multicenter retrospective study involving patients from four hospitals in China. Preoperative multidimensional objective indicators, including clinical data, prostate MRI parameters, and urodynamic measurements, will be collected. The primary outcome is a favorable surgical response defined by a postoperative-to-preoperative International Prostate Symptom Score (IPSS) ratio ≤ 0.5 at 6 months after surgery.\n\nMultivariable logistic regression, restricted cubic splines, and bootstrap internal validation will be used to construct and evaluate the scoring system. The goal is to provide an objective, individualized tool for optimizing surgical decision-making in BPH patients.",[62],"BPH (Benign Prostatic Hyperplasia)","NOT_YET_RECRUITING","2026-05-29",{"date":35,"type":38},{"date":67,"type":22},"2026-06-01",{"date":69,"type":22},"2027-09-01",{"name":44,"class":45},{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":46},"100548449","fapi-and-fdg-petmri-in-diagnosis-and-therapy-prediction-of-bladder-cancer-100548449","NCT06421142","FAPI and FDG PET\u002FMRI in Diagnosis and Therapy Prediction of Bladder Cancer","Application Research of FAPI Positron Emission Tomography(PET)\u002FMRI, 18F-Fluorodeoxyglucose (FDG) PET\u002FMRI, and MRI in the Diagnosis of Muscular Invasive Bladder Cancer and Evaluation of Neoadjuvant Therapy Efficacy","Inclusion Criteria:\n\n* Inclusion criteria for MIBC diagnostic studies\n\n  1. Patients with suspected muscle-invasive bladder cancer;\n  2. Completion of FAPI PET\u002FMRI, FDG PET\u002FMRI and MRI;\n  3. Complete clinical laboratory and pathological data.\n* Inclusion criteria for MIBC neoadjuvant therapy efficacy evaluation study\n\n  1. Patients diagnosed with muscle invasive bladder cancer;\n  2. Completion of FAPI PET\u002FMRI, FDG PET\u002FMRI, and MRI before neoadjuvant therapy;\n  3. Complete clinical laboratory and pathological data.\n\nExclusion Criteria:\n\n* Exclusion criteria for MIBC diagnostic study\n\n  1. Combined with other malignant tumors;\n  2. Not receiving surgical treatment;\n  3. Receiving neoadjuvant therapy before surgery;\n  4. Previous allergy to contrast components or similar components;\n  5. Serious organ function abnormalities, such as heart, lung, liver, kidney function serious abnormalities;\n  6. Incomplete clinicopathological data\n* Exclusion criteria of MIBC neoadjuvant therapy efficacy evaluation study\n\n  1. Combination of other malignant tumors;\n  2. FAPI PET\u002FMRI, FDG PET\u002FMRI and MRI were not completed after neoadjuvant therapy;\n  3. Prior hypersensitivity to contrast components or similar components;\n  4. Serious organ function abnormalities, such as serious abnormalities of heart, lung, liver and kidney function;\n  5. Incomplete clinicopathological data.","80 Years",{"count":80,"type":22},80,[25],"The aim of this trial is to investigate the value of FAPI PET\u002FMRI, FDG PET\u002FMRI and MRI in diagnosing MIBC and predicting the efficacy of neoadjuvant therapy for MIBC patients, so as to guide the clinic to adjust the treatment plan in time and benefit MIBC patients.",[84],"Urinary Bladder Neoplasms",[86,87],"Neoadjuvant Chemotherapy","Neoplasm Staging","2026-05-28",{"date":67,"type":38},{"date":91,"type":38},"2024-08-02",{"date":93,"type":22},"2029-06-01",{"name":44,"class":45},{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":110,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":46},"100587074","psma-petmri-guided-prostate-biopsy-for-pi-rads-3-and-prior-negative-biopsy-100587074","NCT06923657","PSMA PET\u002FMRI-Guided Prostate Biopsy for PI-RADS ≤3 and Prior Negative Biopsy","Application of PSMA PET\u002FMRI-guided Prostate Targeted Biopsy in Patients With PI-RADS ≤ 3 and Negative Previous Biopsy: A Single-center, Prospective, Open-label, Randomized Controlled Trial","Inclusion Criteria:\n\n* Serum PSA \\> 4 ng\u002FmL\n* At least one prior negative prostate biopsy\n* At least two consecutive increases in PSA and\u002For PHI\n* Negative digital rectal examination\n* Multiparametric MRI (mpMRI) indicating a PI-RADS score ≤ 3\n\nExclusion Criteria\n\n* Age ≤ 30 years or \\> 85 years\n* Concurrent presence of other malignant tumors\n* Previous treatment with any form of anti-tumor therapy or prostate surgery (excluding prostate biopsy)\n* Inability to comply with PSMA PET\u002FMRI examination (e.g., contrast allergy, claustrophobia, etc.)\n* Contraindications for prostate biopsy (e.g., coagulation disorders, acute prostatitis, acute urinary tract infection, etc.)\n* Severe organ dysfunction (e.g., significant cardiac, pulmonary, hepatic, or renal impairment)\n* Incomplete clinical or pathological data","85 Years",{"count":104,"type":22},230,[25],"The goal is to provide more accurate diagnostic tools and optimized diagnostic workflows for clinically suspected prostate cancer patients with prior negative biopsies, improving early detection rates for csPCa and reducing missed diagnoses.",[108,109],"Prostate Cancer Screening","PSMA-PET",[111,112,113],"imaging examinations","PSMA PET\u002FMRI","Prostate cancer","2026-05-26",{"date":88,"type":38},{"date":117,"type":38},"2025-05-07",{"date":119,"type":22},"2026-12-01",{"name":44,"class":45},{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":46},"100636188","phase-2-prospective-clinical-trial-of-177lu-p17-088-in-the-treatment-of-metastatic-castration-resistant-prostate-cancer-100636188","NCT07562438","Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer","Prospective Clinical Trial of Low-dose 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer","Inclusion Criteria:\n\n1. Metastatic Castration-Resistant Prostate Cancer (mCRPC) mCRPC refers to prostate cancer that progresses despite serum testosterone at castrate levels (\\\u003C 50 ng\u002FdL or 1.7 nmol\u002FL), meeting at least one of the following criteria:\n\n   * PSA \\>1 ng\u002FmL with two consecutive rises at least 1 week apart, each increase ≥ 50% above the nadir.\n   * Radiographic progression: Either two or more new bone lesions on bone scan, or soft tissue lesion progression as per RECIST 1.1 criteria. Progression based on symptoms alone is insufficient for mCRPC diagnosis and requires further evaluation.\n2. Failure of, Refusal of, Absence of, or Refractoriness to Standard Therapy, or Disease Progression, or No Available Standard Therapy per Current Guidelines:\n\n   * Patients who have not received, refused, or progressed after receiving at least 1 but no more than 2 prior taxane-based therapies. The taxane regimen must have included exposure for at least 2 cycles. Patients who received only one taxane may be included if the investigator deems them unsuitable for a second taxane (e.g., due to frailty assessed by geriatric\u002Fcomorbidity evaluation or intolerance).\n   * Patients who have progressed after receiving at least one novel androgen axis drug \\[NAAD\\] (e.g., abiraterone, enzalutamide).\n3. Ability to understand and voluntarily sign a written informed consent form (ICF), and willingness and ability to comply with trial procedures including examinations and follow-up.\n4. Age 18-90 years (inclusive).\n5. Expected survival \\> 6 months.\n6. ECOG performance status ≤ 2.\n7. Presence of high-uptake lesions confirmed by 68Ga-PSMA-11 PET\u002FCT imaging (positive defined as lesion uptake \\>1.5 times the liver background).\n8. At least one measurable lesion per RECIST 1.1 criteria OR at least one bone metastasis per PCWG3 criteria.\n9. Adequate organ function (No blood products, growth factors, or albumin administered within 14 days prior to baseline lab tests):\n\n   * Bone Marrow Function: Neutrophil count ≥ 1.5 × 10#\u002FL, White blood cell count ≥ 3.0 × 10\\^9\u002FL, Platelet count ≥ 100 × 10\\^9\u002FL, Hemoglobin ≥ 10 g\u002FdL (≥ 100 g\u002FL).\n   * Liver Function: Albumin ≥ 30 g\u002FL, Total bilirubin ≤ 1.5 × ULN, ALT or AST ≤ 3.0 × ULN (without liver metastases) or ≤ 5.0 × ULN (with liver metastases).\n   * Renal Function: Serum creatinine ≤ 1.5 × ULN.\n10. Agreement to comply with prescribed radiation protection measures during the trial period.\n\nExclusion Criteria:\n\n1. Inability to tolerate imaging procedures;\n2. Patients who have received systemic anticancer therapy (e.g., chemotherapy, radiotherapy, immunotherapy; excluding endocrine therapy), investigational drugs, or device therapy within 4 weeks prior to dosing;\n3. Patients who received radionuclide therapy (Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, Lutetium-177) within 6 months, or any External Beam Radiation Therapy (EBRT) within 2 months prior to the first dose;\n4. Patients with unresolved Grade 4 myelosuppression from prior anticancer therapy within 2 weeks, or Grade 3 myelosuppression requiring \\>6 weeks for recovery;\n5. Planned use of cytotoxic chemotherapy, antitumor immunotherapy, radioligand therapy, or similar agents during the study;\n6. Use of blood products or albumin within 14 days before dosing to meet enrollment criteria;\n7. Brain metastasis at screening, except:\n\n   * Asymptomatic cases confined to supratentorial\u002Fcerebellar regions (no midbrain\u002Fpons\u002Fmedulla\u002Fspinal cord involvement) without corticosteroid therapy and with lesions ≤1.5 cm;\n   * Symptomatic cases with treated and radiologically stable lesions (\\>4 weeks);\n8. Other malignancies within 5 years (excluding cured localized cancers like basal\u002Fsquamous cell skin carcinoma);\n9. Superscan on bone scintigraphy;\n10. Symptomatic or impending spinal cord compression;\n11. Prior EBRT involving extensive bone marrow (\\>25%);\n12. Significant cardiac disease at screening, including:\n\n    * QTcF \\>470 ms or long QT syndrome history;\n    * Myocardial infarction, angina, or CABG within 6 months deemed ineligible by investigators;\n13. Any condition that, per investigator judgment, may compromise safety, data interpretation, or indicate high risk;\n14. Uncontrolled bladder outlet obstruction, urinary incontinence, claustrophobia, or radiophobia at screening;\n15. Positive for HCV-Ab, HIV, or syphilis antibodies at screening;\n16. HBsAg-positive patients with active HBV replication (confirmed by HBVDNA per investigator assessment);\n17. Known allergy to proteins\u002Fpeptides, excipients, or structurally related compounds;\n18. History of drug\u002Falcohol abuse within 1 year or chronic substance abuse;\n19. Failure to use effective contraception during the trial and for 6 months post-last dose;\n20. Severe active infection prior to the first administration.","90 Years",{"count":130,"type":22},20,[132],"PHASE2","PSMA is an ideal target for precision diagnosis and treatment of prostate cancer. P17-088 is a novel albumin-binding PSMA-targeted radioligand. This study aims to explore the safety and efficacy of 177Lu-labeled P17-088 for treating patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).",[135],"Prostate Cancer","2026-04-27",{"date":138,"type":38},"2026-05-01",{"date":140,"type":22},"2026-04-29",{"date":142,"type":22},"2028-12-31",{"name":44,"class":45},{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":23,"phases":154,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":46},"100632450","optimizing-parameters-of-low-intensity-focused-ultrasound-for-pallidal-modulation-in-huntingtons-disease-100632450","NCT07513844","Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease","Low-Intensity Focused Ultrasound Stimulation of the External Globus Pallidus in Huntington's Disease: A Phase I\u002FII Safety and Feasibility Trial","Inclusion Criteria:\n\n1. Aged 18 to 75 years (inclusive)\n2. Genetically confirmed Huntington's disease with HTT CAG repeat length of 40 or greater\n3. Unified Huntington's Disease Rating Scale Total Maximal Chorea score of 8 or higher on a scale of 0 to 28, with higher scores indicating more severe chorea\n4. Huntington's Disease Integrated Staging System stage 2 or 3\n5. Willing to participate and provide informed consent\n6. Have a reliable caregiver available\n7. No severe cognitive impairment that would preclude reliable reporting of adverse events or efficacy during treatment\n\nExclusion Criteria:\n\n1. History of self-injury, aggressive behavior, or unstable psychiatric disorders\n2. History of head injury or neurosurgical procedure\n3. Presence of intracranial implants, metallic foreign bodies, cochlear implants, or cardiac pacemakers\n4. Severe systemic disease, pregnancy, or breastfeeding\n5. Contraindications to magnetic resonance imaging, ultrasound, or anesthesia\n6. Prior treatment with electroconvulsive therapy, transcranial magnetic stimulation, transcranial direct current stimulation, transcranial alternating current stimulation, or other neuromodulation therapies within the past 3 years\n7. Severe brain atrophy with unclear external globus pallidus structure on MRI\n8. Concurrent participation in another interventional clinical trial\n9. Any other condition that, in the opinion of the investigator, would preclude participation","75 Years",{"count":153,"type":22},24,[25],"The purpose of this research study is to determine the optimal pulse repetition frequency of low-intensity focused ultrasound that is safe and effective in improving motor symptoms in patients with Huntington's disease.",[157],"Huntington Disease",[159,157,160,161],"low intensity focused ultrasound","brain stimulation","ultrasonic stimulation","2026-04-23",{"date":140,"type":38},{"date":165,"type":38},"2026-04-20",{"date":167,"type":22},"2027-03-31",{"name":44,"class":45},{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":78,"enrollmentInfo":176,"targetDuration":178,"studyType":59,"phases":4,"briefSummary":179,"conditions":180,"keywords":185,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":46},"100635008","study-on-construction-of-whole-lifecycle-cohort-big-data-management-and-clinical-prognosis-of-cardio-renal-metabolic-ckm-syndrome-100635008","NCT07547098","Study on Construction of Whole Lifecycle Cohort, Big Data Management and Clinical Prognosis of Cardio-Renal-Metabolic (CKM) Syndrome","CKM-LCBP","Inclusion Criteria:\n\n* Age 18 years or older.\n* Inpatient record available at the First Affiliated Hospital of Fujian Medical University with retrievable identifiers for data linkage.\n* Cardiovascular disease, kidney disease, metabolic disease, or key examination\u002Flaboratory information supporting CKM phenotyping.\n* Willingness to participate and provision of written informed consent.\n* Ability to complete baseline assessment and follow-up.\n* Full civil capacity and ability to understand study information.\n\nExclusion Criteria:\n\n* Refusal to provide written informed consent.\n* Severe psychiatric disease or cognitive impairment precluding participation.\n* End-stage disease with expected survival less than 1 year.\n* Long-term absence more than 6 months preventing reliable follow-up.\n* Participation in another clinical study that may interfere with endpoint adjudication.\n* Missing key fields preventing linkage of examinations, imaging, and outcomes.",{"count":177,"type":22},8000,"5 Years","This is a single-center observational registry study aiming to establish a structured clinical and multimodal imaging database for cardiovascular-kidney-metabolic (CKM) populations and to support lifecycle follow-up and outcome management. Adult patients aged 18-80 years with cardiovascular, kidney, and\u002For metabolic diseases or key data for CKM phenotyping will be enrolled at the First Affiliated Hospital of Fujian Medical University. The study integrates retrospective data entry and prospective follow-up, including clinical records, laboratory tests, medications, electrocardiography, echocardiography, vascular function assessment, carotid and abdominal ultrasound, bone density, coronary CTA and post-processing data. The primary outcome is the first occurrence of a cardiorenal composite endpoint. Participants will be followed for up to 5 years through active annual follow-up and passive monthly data updates to support risk stratification, real-world evidence generation, and CKM management pathway optimization.",[181,182,183,184],"Cardiovascular Diseases (CVD)","Chronic Kidney Disease","Metabolic Diseases","Cardiovascular-kidney-metabolic Syndrome",[186,187,188,189],"CKM syndrome","Cardiovascular-Kidney-Metabolic","Patient registry","Real-world data","2026-04-19",{"date":162,"type":38},{"date":193,"type":38},"2026-03-01",{"date":195,"type":22},"2031-02-28",{"name":44,"class":45},{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":205,"conditions":206,"keywords":208,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":218,"locationsCount":46},"100622033","evaluation-of-ai-large-models-for-diagnosis-and-treatment-in-real-world-cases-multicenter-retrospective-study-100622033","NCT07378358","Evaluation of AI Large Models for Diagnosis and Treatment in Real-World Cases: Multicenter Retrospective Study","Inclusion Criteria:\n\n* The case data is sourced from the four hospitals involved in the study, with complete and authentic diagnosis and treatment records.\n* Patients must be 18 years or older, with no gender restrictions.\n* Complete medical records, including the following core information: patient' s basic information, present illness history, past medical history, physical examination, and auxiliary examinations (including laboratory and imaging tests).\n* A clear discharge diagnosis and treatment plan (including therapeutic measures and follow-up arrangements).\n* Medical records have been archived, with objective and accurate information that has not been altered.\n* The patient or their legal representative has provided informed consent, agreeing to the use of their anonymized medical data for research analysis.\n\nExclusion Criteria:\n\n* Medical records with significant missing information, such as key clinical details (present illness history, diagnostic or treatment records, etc.).\n* Cases where the diagnosis or treatment plan is unclear, or where treatment has not been fully completed for an initial diagnosis.\n* Cases where the primary diagnosis is not urological.\n* Cases with major errors or inconsistencies in the records that could affect further assessment.\n* Medical records in special formats or images that are not readable (e.g., handwritten notes, non-standard documentation).\n* Patients who have not signed the informed consent form or who refuse to allow their medical data to be used for research.",{"count":204,"type":22},800,"This multicenter retrospective study aims to evaluate the diagnostic and therapeutic performance of three large language models-ChatGPT, Gemini and Deepseek-using 800 archived inpatient medical records from urology departments across four tertiary hospitals. The study will focus on the accuracy and applicability of these models in disease recognition, preliminary diagnosis and treatment recommendation generation, in order to explore their potential value and limitations in supporting clinical decision-making in real-world settings.",[207],"Urologic Diseases",[209,207,210,211],"Large Language Models","Clinical Decision Support","Retrospective Study","2026-01-26",{"date":214,"type":38},"2026-01-30",{"date":216,"type":22},"2026-01-01",{"date":67,"type":22},{"name":44,"class":45},{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":23,"phases":229,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":4},"100621344","deep-brain-stimulation-of-the-nucleus-accumbens-and-anterior-limb-of-the-internal-capsule-in-the-treatment-of-refractory-schizophrenia-100621344","NCT07369401","Deep Brain Stimulation of the Nucleus Accumbens and Anterior Limb of the Internal Capsule in the Treatment of Refractory Schizophrenia","Efficacy and Safety of Deep Brain Stimulation of the Nucleus Accumbens and Anterior Limb of the Internal Capsule in the Treatment of Refractory Schizophrenia: A Prospective, Single-Center, Double-Blind, Randomized Controlled Study","Inclusion Criteria:\n\n* Aged 18-55 years (inclusive) at the time of signing the informed consent form, male or non-pregnant female;\n* Meets the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for schizophrenia;\n* Schizophrenia disease course ≥ 5 years before screening;\n* Meets the 2016 TRRIP criteria for refractory\u002Fultra-refractory schizophrenia: previous treatment with ≥ 2 non-clozapine antipsychotics at adequate dose (≥ 600mg\u002Fday chlorpromazine equivalent) and duration (≥ 12 weeks) with no response or intolerance, or clozapine at adequate dose (≥ 300mg\u002Fday or plasma concentration ≥ 350ng\u002Fml) and duration (≥ 12 weeks) with no response or intolerance, plus moderate or greater symptom severity;\n* PANSS total score ≥ 70 at screening and baseline;\n* No changes in medication regimen in the past 2 months;\n* The patient and their guardian have been fully informed and signed the informed consent form.\n\nExclusion Criteria:\n\n* Comorbid with epilepsy, severe cognitive impairment (Mini-Mental State Examination \\[MMSE\\] score \\\u003C 10), organic mental disorder, paranoid personality disorder, mental retardation, or addiction (other than nicotine);\n* Has implanted devices such as cochlear implants or cardiac pacemakers, or has undergone surgery that may affect the trial within 6 months;\n* Has contraindications to DBS implantation and is deemed unsuitable for surgery by the investigator;\n* Has participated in other drug\u002Fmedical device clinical trials within 3 months before screening;\n* Confirmed HIV-positive;\n* Pregnant\u002Flactating women, women of childbearing age with positive HCG\u002Furine pregnancy test at screening, those unable to use effective contraception during the trial, or those planning to conceive within 3 months after trial initiation;\n* Other conditions deemed unsuitable for participation by the investigator.","55 Years",{"count":228,"type":22},10,[25],"Schizophrenia is a lifelong psychiatric disorder with a prevalence rate of 0.559% and a lifetime prevalence rate of 0.588% among Chinese adults. It often causes social dysfunction and psychiatric disability, shortening patients' life expectancy by 10-25 years compared to the general population. Approximately 30% of patients are resistant to antipsychotic medications, and 60% of these do not respond to clozapine (ultra-refractory). DBS has shown definite efficacy in movement disorders and refractory obsessive-compulsive disorder (OCD) as well as major depressive disorder (MDD). Preliminary studies have indicated that DBS targeting sites such as the NAcc can improve symptoms in some schizophrenia patients. Additionally, abnormal white matter in the anterior limb of the internal capsule has been identified in refractory patients, providing a basis for exploring combined target stimulation.\n\nThis study aims to investigate the efficacy and safety of deep brain stimulation of the Nucleus Accumbens and Anterior Limb of the Internal Capsule in the treatment of refractory schizophrenia. A randomized controlled (self-controlled) design is adopted. The statistical analysis unit generates a random allocation table using SAS software, and groups are assigned via central randomization. Both groups undergo three stimulation phases: DBS activation 2 weeks after surgery, 6 weeks of single-target stimulation followed by 2 weeks of shutdown, another 6 weeks of alternate single-target stimulation followed by 2 weeks of shutdown, and finally 6 weeks of combined dual-target stimulation. Trial Group 1 is stimulated sequentially at NAcc, Anterior Limb of the Internal Capsule, and dual targets; Trial Group 2 follows the reverse order for single-target stimulation before combined stimulation. Surgery is performed under general anesthesia by neurosurgeons with associate senior titles or above and extensive experience. After head frame placement, CT and MRI images are fused for targeting. Electrodes are implanted into the NAcc via the Anterior Limb of the Internal Capsule, and a pulse generator is placed under the clavicle and connected to the electrodes. Postoperative CT confirms electrode position. Trial devices are provided by Jingyu Medical Technology (Suzhou) Co., Ltd., including implantable neurostimulation systems, electrode leads, extension leads, and programming equipment. On-site follow-up is conducted at key time points: screening, baseline, 2 weeks postoperatively (DBS activation), 6 weeks after stimulation, 16 weeks postoperatively, and 24 weeks postoperatively, including scale assessments, physical examinations, and laboratory\u002Fimaging tests. The primary outcome measure was the reduction rate of the total PANSS score at 24 weeks after DBS implantation compared to baseline, with a 20% reduction defined as effective, assessed by independent psychiatric evaluators.",[232],"Refractory Schizophrenia",[234,232,235,236],"Deep Brain Stimulation","Nucleus Accumbens","Anterior Limb","2026-01-18",{"date":239,"type":38},"2026-01-27",{"date":241,"type":22},"2026-01-20",{"date":243,"type":22},"2026-12-31",{"name":44,"class":45},{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":128,"enrollmentInfo":252,"targetDuration":4,"studyType":23,"phases":254,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":46},"100620889","phase-1-sequential-study-of-225ac-lnc1011-in-the-treatment-of-metastatic-castration-resistant-prostate-cancer-100620889","NCT07363486","Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer","Prospective Sequential Study of Dose-Escalating 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer","Inclusion Criteria:\n\n1. Metastatic Castration-Resistant Prostate Cancer (mCRPC) mCRPC refers to prostate cancer that progresses despite serum testosterone at castrate levels (\\\u003C 50 ng\u002FdL or 1.7 nmol\u002FL), meeting at least one of the following criteria:\n\n   * PSA \\>1 ng\u002FmL with two consecutive rises at least 1 week apart, each increase ≥50% above the nadir.\n   * Radiographic progression: Either two or more new bone lesions on bone scan, or soft tissue lesion progression as per RECIST 1.1 criteria. Progression based on symptoms alone is insufficient for mCRPC diagnosis and requires further evaluation.\n2. Failure of, Refusal of, Absence of, or Refractoriness to Standard Therapy, or Disease Progression, or No Available Standard Therapy per Current Guidelines:\n\n   * Patients who have not received, refused, or progressed after receiving at least 1 but no more than 2 prior taxane-based therapies. The taxane regimen must have included exposure for at least 2 cycles. Patients who received only one taxane may be included if the investigator deems them unsuitable for a second taxane (e.g., due to frailty assessed by geriatric\u002Fcomorbidity evaluation or intolerance).\n   * Patients who have progressed after receiving at least one novel androgen axis drug \\[NAAD\\] (e.g., abiraterone, enzalutamide).\n3. Ability to understand and voluntarily sign a written informed consent form (ICF), and willingness and ability to comply with trial procedures including examinations and follow-up.\n4. Age 18-90 years (inclusive).\n5. Expected survival \\> 6 months.\n6. ECOG performance status ≤ 2.\n7. Presence of high-uptake lesions confirmed by 68Ga-PSMA-11 PET\u002FCT imaging (positive defined as lesion uptake \\>1.5 times the liver background).\n8. At least one measurable lesion per RECIST 1.1 criteria OR at least one bone metastasis per PCWG3 criteria.\n9. Adequate organ function (No blood products, growth factors, or albumin administered within 14 days prior to baseline lab tests):\n\n   * Bone Marrow Function: Neutrophil count ≥ 1.5 × 10#\u002FL, White blood cell count ≥ 3.0 × 10#\u002FL, Platelet count ≥ 100 × 10#\u002FL, Hemoglobin ≥ 10 g\u002FdL (≥ 100 g\u002FL).\n   * Liver Function: Albumin ≥ 30 g\u002FL, Total bilirubin ≤ 1.5 × ULN, ALT or AST ≤ 3.0 × ULN (without liver metastases) or ≤ 5.0 × ULN (with liver metastases).\n   * Renal Function: Serum creatinine ≤ 1.5 × ULN.\n   * Coagulation: INR ≤ 1.5; Activated partial thromboplastin time (APTT) ≤ 2 × ULN (for patients not on anticoagulation or on stable-dose anticoagulation).\n10. Agreement to comply with prescribed radiation protection measures during the trial period.\n\nExclusion Criteria:\n\n1. Inability to tolerate imaging procedures;\n2. Patients who have received systemic anticancer therapy (e.g., chemotherapy, radiotherapy, immunotherapy; excluding endocrine therapy), investigational drugs, or device therapy within 4 weeks prior to dosing;\n3. Patients who received radionuclide therapy (Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, Lutetium-177) within 6 months, or any External Beam Radiation Therapy (EBRT) within 2 months prior to the first dose;\n4. Patients with unresolved Grade 4 myelosuppression from prior anticancer therapy within 2 weeks, or Grade 3 myelosuppression requiring \\>6 weeks for recovery;\n5. Planned use of cytotoxic chemotherapy, antitumor immunotherapy, radioligand therapy, or similar agents during the study;\n6. Use of blood products or albumin within 14 days before dosing to meet enrollment criteria;\n7. Brain metastasis at screening, except:\n\n   * Asymptomatic cases confined to supratentorial\u002Fcerebellar regions (no midbrain\u002Fpons\u002Fmedulla\u002Fspinal cord involvement) without corticosteroid therapy and with lesions ≤1.5 cm;\n   * Symptomatic cases with treated and radiologically stable lesions (\\>4 weeks);\n8. Other malignancies within 5 years (excluding cured localized cancers like basal\u002Fsquamous cell skin carcinoma);\n9. Superscan on bone scintigraphy;\n10. Symptomatic or impending spinal cord compression;\n11. Prior EBRT involving extensive bone marrow (\\>25%);\n12. Significant cardiac disease at screening, including:\n\n    * QTcF \\>470 ms or long QT syndrome history;\n    * Myocardial infarction, angina, or CABG within 6 months deemed ineligible by investigators;\n13. Any condition that, per investigator judgment, may compromise safety, data interpretation, or indicate high risk;\n14. Uncontrolled bladder outlet obstruction, urinary incontinence, claustrophobia, or radiophobia at screening;\n15. Positive for HCV-Ab, HIV, or syphilis antibodies at screening;\n16. HBsAg-positive patients with active HBV replication (confirmed by HBVDNA per investigator assessment);\n17. Known allergy to proteins\u002Fpeptides, excipients, or structurally related compounds;\n18. History of drug\u002Falcohol abuse within 1 year or chronic substance abuse;\n19. Failure to use effective contraception during the trial and for 6 months post-last dose;\n20. Severe active infection prior to the first administration.",{"count":253,"type":22},9,[255,132],"PHASE1","PSMA is an ideal target for the precise diagnosis and treatment of prostate cancer. LNC1011 is a novel albumin-binding PSMA-targeted compound. This study aims to investigate the safety and efficacy of different doses of 225Ac-labeled LNC1011 in the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) and to explore the optimal therapeutic dose.",[135],"2026-01-16",{"date":260,"type":38},"2026-01-23",{"date":262,"type":38},"2025-04-01",{"date":264,"type":22},"2027-12-31",{"name":44,"class":45},{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":128,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":279,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":283,"locationsCount":46},"100620881","phase-1-the-value-of-grpr-pet-imaging-for-diagnosis-and-staging-in-prostate-cancer-100620881","NCT07363382","The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer","The Value of Gastrin-Releasing Peptide Receptor (GRPR) PET Imaging for Diagnosis and Staging in Prostate Cancer","Inclusion Criteria:\n\n* confirmed treated or untreated prostate cancer patients;\n* signed written consent.\n\nExclusion Criteria:\n\n* known allergy against PSMA;\n* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.",{"count":274,"type":22},6,[255,132],"The gastrin-releasing peptide receptor (GRPR) is highly expressed in prostate cancer (77%-100%). Numerous studies have confirmed that GRPR PET imaging has emerged as a significant molecular imaging modality in prostate cancer, particularly serving as a complementary tool to PSMA PET for addressing cases with negative or insufficient PSMA expression. It demonstrates substantial value in initial staging (especially in intermediate- and high-risk patients), detecting sites of biochemical recurrence, assessing metastatic lesions (notably in mCRPC), and guiding treatment decisions. 68Ga-G21 and 68Ga-G23 are two novel molecular probes targeting GRPR. This study aims to evaluate their biodistribution and diagnostic performance in prostate cancer and compare them with 68Ga-PSMA-11 PET imaging.",[278],"Prostate Cancer (Adenocarcinoma)",{"date":260,"type":38},{"date":281,"type":38},"2025-12-20",{"date":264,"type":22},{"name":44,"class":45},{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":56,"enrollmentInfo":291,"targetDuration":4,"studyType":23,"phases":293,"briefSummary":294,"conditions":295,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":46},"100618911","comparing-different-doses-of-corticosteroids-in-local-infiltration-analgesia-lia-for-total-knee-arthroplasty-100618911","NCT07337772","Comparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty","Prospective Randomized Controlled Trial Comparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty","Inclusion Criteria:\n\n1. Male or female participants aged 18 years or older;\n2. Undergoing primary unilateral total knee arthroplasty (TKA)for unilateral knee osteoarthritis(OA)at ourhospital;\n3. Preoperative American Society of Anesthesiologists(ASA)physical status classification of 1-3;\n4. Ability to provide informed consent and sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Previous surgery on the operative knee or a history of infection in the operative knee;\n2. Non-osteoarthritis conditions (including rheumatoid arthritis, traumatic arthritis, septic arthritis, and hemophilic arthritis);\n3. Severe osteoarthritis (including flexion contracture \\>30° or varus\u002Fvalgus deformity \\>30°);\n4. Allergy to the relevant study drugs;\n5. Presence of neuromuscular dysfunction in the ipsilateral limb;\n6. Dependence on anesthetic drugs (defined as weekly use of opioids exceeding 100 mg morphine equivalents or local anesthetics for preoperative pain control for more than 3 months);\n7. Poor systemic condition, including but not limited to: glycated hemoglobin (HbA1c) level \\>12%; blood pressure \\>170\u002F110 mmHg (1 mmHg = 0.133 kPa); history of myocardial infarction, stroke, transient ischemic attack, acute congestive heart failure, or any acute coronary event within 6 months; dialysis or renal transplantation; pregnancy or lactation.",{"count":292,"type":22},120,[25],"This study aims to compare the efficacy of different doses of glucocorticoids in local infiltration analgesia (LIA) during total knee arthroplasty (TKA) through a prospective single-center randomized controlled trial, and to explore the safety and feasibility of high-dose glucocorticoids. Through this research, the investigators hope to provide an optimized solution for post-TKA pain management, improve patients' postoperative recovery and quality of life, and offer scientific evidence for pain management following TKA.",[296,297,298],"Adrenal Cortex Hormones","Arthroplasty, Replacement, Knee","Anesthesia, Local","2026-01-04",{"date":301,"type":38},"2026-01-13",{"date":303,"type":22},"2026-02-01",{"date":305,"type":22},"2028-11-01",{"name":44,"class":45},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":78,"enrollmentInfo":314,"targetDuration":4,"studyType":23,"phases":316,"briefSummary":317,"conditions":318,"keywords":320,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":46},"100617022","rifampin-combined-antibiotic-therapy-for-staphylococcal-pji-100617022","NCT07313215","Rifampin-combined Antibiotic Therapy for Staphylococcal PJI","The Efficacy and Complications of Rifampin-combined Antibiotic Therapy for Staphylococcal Periprosthetic Joint Infections（PJI）: A Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosed as PJI according to the MSIS criteria\n\n  * The pathogenic bacteria were identified as Staphylococcus through microbial culture and drug sensitivity tests were conducted\n\n    * There are complete clinical data ④ Age under 80 years old, without serious complications or immunosuppressive status ⑤ The patient voluntarily participated in this study and was physically and mentally tolerant of the treatment process and various tests in this study. They have signed the informed consent form and passed the review of the ethics committees of all hospitals participating in this study\n\nExclusion Criteria:\n\n* Those with chronic inflammation in other parts of the body before the operation\n\n  * Non-staphylococcal infection or mixed infection\n\n    * The patient has other diseases that may affect the outcome, such as immune deficiency or liver and kidney dysfunction ④ Those with an expected lifespan of less than half a year ⑤ The researcher determined that the patient no longer met the criteria of this study due to compliance issues",{"count":315,"type":22},428,[25],"This is a prospective, multicenter, randomized controlled study. Patients were evaluated through inclusion and exclusion criteria. Patients who meet the conditions will sign an informed consent form. After DAIR surgery, they will be treated with intravenous antibiotics for 1-2 weeks and then randomly assigned to one of the following two groups: Antibiotic treatment group: All enrolled patients will be treated with antibiotics (fluoroquinolones or linezolid) for 3 months based on the results of microbial culture and drug sensitivity after surgery. Rifampicin combined with antibiotics treatment group: In addition to the above-mentioned antibiotics, all enrolled patients were treated with rifampicin for 3 months after the operation. The infection control rates of the two groups were judged through at least 2-year follow-up after the operation.The study will follow the Consolidated Standards of Reporting Trials (CONSORT) guidelines for reporting parallel group randomised trials. Ethical approval will be obtained from each institution. Written informed consent will be obtained from all participants to ensure their voluntary participation and understanding of the study.",[319],"Periprosthetic Joint Infection",[319,321,322],"Debride ment, antibiotics, and implant retention","Revision","2025-12-17",{"date":325,"type":38},"2025-12-31",{"date":327,"type":38},"2025-11-13",{"date":329,"type":22},"2027-12-18",{"name":44,"class":45},{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":338,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":341,"conditions":342,"keywords":350,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":46},"100616646","taining-golden-lake-comprehensive-chronic-disease-management-initiative-100616646","NCT07308314","Taining Golden Lake Comprehensive Chronic Disease Management Initiative","TAIGOLD-CDM","Inclusion Criteria:\n\n* Age ≥18 years, male or female.\n* Resident of Taining County for ≥6 months and expected to remain in the county for at least the next 3 years.\n* Full civil capacity and able to understand study procedures.\n* Willing to voluntarily participate and provide written informed consent.\n* Able to complete baseline survey and follow-up visits.\n\nExclusion Criteria:\n\n* Refusal to sign informed consent.\n* Severe psychiatric disorders or cognitive impairment preventing participation.\n* End-stage disease with expected survival \\\u003C1 year.\n* Long-term migrants (≥6 months per year outside the county), unable to guarantee follow-up.\n* Participation in other clinical studies that may interfere with this research.",true,{"count":340,"type":22},20000,"This study aims to establish the first county-level, population-based prospective cohort in Taining County, Fujian Province, China. The cohort will include at least 20,000 residents aged 18 years or older. The project will systematically collect questionnaires, physical measurements, laboratory tests, imaging data, and biological samples to build a multi-dimensional health database and biobank. Through 3-year follow-up, the study seeks to reveal the epidemiological patterns and risk factors of chronic diseases, characterize the natural course of multimorbidity and aging syndromes, and develop a comprehensive chronic disease management model suitable for rural and mountainous regions.",[343,344,345,346,347,348,349],"Chronic Disease","Chronic Disease Management","Hypertension","Diabetes Mellitus","Dyslipidemias","Frailty","Sarcopenia",[344,351,345,346,352,353,348,349,354,355],"Prospective Cohort","Dyslipidemia","Cardiovascular Disease","Aging","Healthy Aging","2025-12-15",{"date":358,"type":38},"2025-12-29",{"date":360,"type":38},"2025-08-01",{"date":362,"type":22},"2028-07-01",{"name":44,"class":45},{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":373,"conditions":374,"keywords":376,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":384,"locationsCount":46},"100612744","combined-use-of-bacteroides-fragilis-and-bcaas-on-hbsag-clearance-100612744","NCT07257562","Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance","A Prospective Observational Study on the Effects of Concomitant Administration of Bacteroides Fragilis and Branched-Chain Amino Acids on HBsAg Clearance","Inclusion Criteria:\n\n\\- chronic hepatitis B patients\n\nExclusion Criteria:\n\n* patients with malignancies\n* patients with other liver diseases\n* pregnancy patients",{"count":372,"type":22},40,"The goal of this prospective observational study is to determine the effects of concomitant administration of Bacteroides fragilis and Branched-Chain Amino Acids on hepatitis B virus clearance. The primary question it aims to answer is whether this concomitant administration can promote HBV clearance.\n\nThe study will observe the HBV clearance rate in chronic hepatitis B patients who receive Bacteroides fragilis and BCAA as a supplement to their routine antiviral therapy. For comparison, researchers will compare the clearance rate in this group to that observed in a control group of chronic hepatitis B patients receiving a standard antiviral regimen based on PegIFNα2b and nucleoside analogs.",[375],"Chronic Hepatitis B",[377],"Hepatitis B","2025-12-01",{"date":380,"type":38},"2025-12-02",{"date":382,"type":38},"2025-06-01",{"date":119,"type":22},{"name":44,"class":45},{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":78,"enrollmentInfo":392,"targetDuration":4,"studyType":23,"phases":394,"briefSummary":395,"conditions":396,"keywords":397,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":46},"100609077","phase-1-68ga-p16-093-pet-imaging-for-diagnosing-prostate-cancer-a-head-to-head-comparison-with-mpmri-100609077","NCT07209865","68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI","68Ga-P16-093 PET Imaging in the Diagnostic Study of Newly Diagnosed, Untreated Prostate Cancer, With a Head-to-head Comparison to mpMRI","Inclusion Criteria:\n\n* Biopsy-confirmed adenocarcinoma of the prostate.\n* No anti-tumor treatment received prior to the PET imaging.\n* Subjects provide signed informed consent and confirm that they are able and willing to comply with all protocol requirements.\n* Radical prostatectomy scheduled within 28 days after PET imaging.\n\nExclusion Criteria:\n\n* Patients with other malignant tumors\n* Subjects with any medical condition or other circumstance that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completion.",{"count":393,"type":22},50,[255,132],"68Ga-P16-093 is a novel radiotracer targeting PSMA. In this study, we investigated the diagnostic efficacy of 68Ga-P16-093 PET imaging (PET\u002FCT or PET\u002FMRI) in patients with newly diagnosed, treatment-naive prostate cancer, and performed a head-to-head comparison with multi-parameter magnetic resonance imaging (mpMRI).",[278],[398,113,399,400],"PSMA","PET imaging","mpMRI","2025-09-30",{"date":403,"type":38},"2025-10-07",{"date":405,"type":38},"2024-10-01",{"date":407,"type":22},"2026-06-30",{"name":44,"class":45},{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":78,"enrollmentInfo":416,"targetDuration":4,"studyType":23,"phases":417,"briefSummary":419,"conditions":420,"keywords":421,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":422,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":426,"locationsCount":46},"100609078","phase-2-68ga-psma-11-pet-imaging-for-diagnosing-prostate-cancer-a-head-to-head-comparison-with-mpmri-100609078","NCT07209878","68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI","68Ga-PSMA-11 PET Imaging in the Diagnostic Study of Newly Diagnosed, Untreated Prostate Cancer, With a Head-to-head Comparison to mpMRI","Inclusion Criteria:\n\n* Biopsy-confirmed adenocarcinoma of the prostate.\n* No anti-tumor treatment received prior to the PET imaging.\n* Subjects provide signed informed consent and confirm that they are able and willing to comply with all protocol requirements.\n* Radical prostatectomy scheduled within 28 days after PET imaging\n\nExclusion Criteria:\n\n* Patients with other malignant tumors\n* Subjects with any medical condition or other circumstance that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completion.",{"count":21,"type":22},[132,418],"PHASE3","68Ga-PSMA-11 is a widely used radiotracer targeting PSMA. In this study, we investigated the diagnostic efficacy of 68Ga-PSMA-11 PET imaging (PET\u002FCT or PET\u002FMRI) in patients with newly diagnosed, treatment-naive prostate cancer, and performed a head-to-head comparison with multi-parameter magnetic resonance imaging (mpMRI).",[278],[398,113,399,400],{"date":403,"type":38},{"date":424,"type":38},"2020-01-10",{"date":407,"type":22},{"name":44,"class":45},{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":435,"targetDuration":437,"studyType":59,"phases":4,"briefSummary":438,"conditions":439,"keywords":441,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":46},"100603032","ph-dypred-a-multimodal-dynamic-risk-prediction-study-in-pulmonary-hypertension-100603032","NCT07131241","PH-DyPred: A Multimodal Dynamic Risk Prediction Study in Pulmonary Hypertension","Research on Dynamic Risk Prediction for Patients With Pulmonary Hypertension Based on Multimodal Data Fusion: A Prospective Observational Study","PH-DyPred","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Pulmonary artery systolic pressure (PASP) ≥35 mmHg as estimated by echocardiography\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Severe hepatic or renal insufficiency\n* Malignancy under active treatment\n* Severe infection\n* Active autoimmune disease\n* Major surgery within the past 3 months\n* Pregnant or breastfeeding women\n* Severe psychiatric disorder impairing ability to comply with the study protocol",{"count":436,"type":22},1000,"2 Years","Pulmonary hypertension (PH) is a progressive cardiopulmonary disease characterized by elevated pulmonary artery pressure and vascular remodeling, which leads to right heart failure and increased mortality. Despite advances in diagnostics, risk stratification remains limited due to the disease's heterogeneity. This study aims to develop and validate a dynamic risk prediction model for PH by integrating multimodal data-including echocardiography, Cardiac MRI, PET-MR, ECG, biomarkers, and clinical features-using advanced machine learning algorithms. The study will establish a prospective cohort of PH patients to explore predictive markers, stratify prognosis, and provide a scientific basis for early warning and individualized management.",[440],"Pulmonary Hypertension",[440,442,443,444,445,446],"Dynamic Risk Prediction","Multimodal Data Fusion","Echocardiography","Right Heart Function","Cardiac Magnetic Resonance","2025-08-27",{"date":449,"type":38},"2025-08-28",{"date":451,"type":38},"2025-06-27",{"date":453,"type":22},"2029-06-30",{"name":44,"class":45},{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":459,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":78,"enrollmentInfo":460,"targetDuration":4,"studyType":23,"phases":461,"briefSummary":462,"conditions":463,"keywords":465,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":46},"100597307","phase-1-research-on-the-application-of-68ga-psma-cyc-pet-imaging-in-the-diagnosis-staging-and-restaging-of-prostate-cancer-100597307","NCT07056790","Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer",{"count":372,"type":22},[255,132],"68Ga-PSMA-CYC is a novel radiotracer targeting PSMA. In this study, we investigated the safety, biodistribution, radiation dosimetry of 68Ga-PSMA-CYC PET\u002FCT in patients with prostate cancer, and performed a head-to-head comparison with 68Ga-PSMA-617 and 68Ga-PSMA-11 to evaluate its diagnostic performance.",[464],"Prostate CA",[466,467],"psma","prostate cancer","2025-06-30",{"date":470,"type":38},"2025-07-09",{"date":472,"type":38},"2025-05-15",{"date":474,"type":22},"2027-05",{"name":44,"class":45},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":338,"sex":18,"minAge":19,"maxAge":128,"enrollmentInfo":482,"targetDuration":4,"studyType":23,"phases":484,"briefSummary":486,"conditions":487,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":495,"locationsCount":46},"100592634","early-phase-1-dosimetry-and-preliminary-clinical-application-study-of-a-novel-probe-targeting-cd73-100592634","NCT06995976","Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73","Inclusion Criteria:\n\nSigned informed consent and be able to follow up.\n\nExclusion Criteria:\n\nPregnant or lactational women; who suffered from severe hepatic and renal insufficiency.",{"count":483,"type":22},30,[485],"EARLY_PHASE1","As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers. Furthermover, we conducted a comparative analysis of 68Ga-dPNE and 18F-FDG imaging to assess both the radiation dosimetry and diagnostic efficacy of 68Ga-dPNE.",[488],"Malignant Tumour","2025-05-21",{"date":491,"type":38},"2025-05-30",{"date":493,"type":38},"2025-03-01",{"date":193,"type":22},{"name":44,"class":45},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":54,"minAge":4,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":23,"phases":504,"briefSummary":505,"conditions":506,"keywords":510,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":46},"100591244","improved-robotic-assisted-radical-prostatectomy-for-locally-advanced-prostate-cancer-bladder-suspension-and-preliminary-outcomes-100591244","NCT06977906","Improved Robotic-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer: Bladder Suspension and Preliminary Outcomes","Inclusion Criteria:\n\n1. prostate biopsy and clinical confirmation of high-risk prostate cancer (PSA \\> 20 ng\u002FmL, Gleason score ≥ 8, or cT stage ≥ T2c) followed by robotic-assisted radical prostatectomy\n2. multiparametric MRI (mpMRI) with a 3.0 T scanner for prostate or pelvic scans performed within 30 days before the operation at our center\n3. Eastern Cooperative Oncology Group (ECOG) performance status score between 0 and 1\n4. Complete clinical and prostate biopsy pathological data.\n5. General health is good, with no infections, autoimmune diseases, hematologic disorders, or other malignancies.\n\nExclusion Criteria:\n\n1. Presence of surgical contraindications.\n2. refusal of enhanced mpMRI imaging.",{"count":503,"type":22},300,[25],"This study is a prospective, single-center clinical trial. It aims to establish an improved robotic-assisted radical prostatectomy for treating locally advanced prostate cancer. The technique evaluates the impact of preserving the anterior peritoneum of the bladder on postoperative bladder descent and urinary control recovery. A retrospective analysis compares this modified approach with traditional anterior approach surgery, assessing differences in oncological outcomes, early functional recovery, and postoperative complication rates. The goal is to provide new theoretical foundations and technical support for the prevention and treatment of postoperative urinary incontinence.",[507,508,509],"Robotic-Assisted Radical Prostatectomy","Locally Advanced Prostate Cancer","Bladder Suspension",[507,508,509],"2025-05-12",{"date":513,"type":38},"2025-05-18",{"date":515,"type":38},"2024-01-01",{"date":517,"type":22},"2027-01-01",{"name":44,"class":45},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":18,"minAge":526,"maxAge":527,"enrollmentInfo":528,"targetDuration":4,"studyType":23,"phases":529,"briefSummary":530,"conditions":531,"keywords":537,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":547,"leadSponsor":549,"locationsCount":4},"100584686","rehabilitation-paired-with-vns-for-motor-function-recovery-100584686","NCT06892574","Rehabilitation Paired with VNS for Motor Function Recovery","A Trial of Rehabilitation Paired with VNS for Motor Function Recovery in Post-ICH Patients (Recovery Study)","Inclusion Criteria:\n\n* Age ≥22 years and \\\u003C80 years, all gender is acceptable.\n* History of unilateral supratentorial intracerebral hemorrhage ≥ 6 months but \\\u003C 5 years.\n* Upper Extremity motor section of the Fugl-Meyer Assessment score ≥20 and ≤50.\n* Right- or left-sided weakness of upper extremity.\n* Ability to communicate, understand, and give appropriate consent. Subjects can follow trial commands.\n* Subjects have good compliance and can complete the visits after surgery.\n\nExclusion Criteria:\n\n* History of ischemic stroke.\n* Cerebral hemorrhage resulting from tumors, trauma, aneurysms, or hemorrhagic transformation of ischemic stroke.\n* Presence of ongoing dysphagia or aspiration difficulties.\n* Prior injury to vagus nerve, either bilateral or unilateral.\n* Subject receiving medication that may significantly interfere with actions of VNS on neurotransmitter systems at study entry, clinic rehabilitation follow-up timepoint, or home rehabilitation follow-up timepoint, such as centrally acting cholinoceptor blockers, centrally acting adrenoceptor blockers, norepinephrine re-uptake inhibitors, etc.\n* Botox injections within 4 weeks prior to enrollment through the unmasking follow-up timepoint (Visit 6).\n* Severe spasticity of the upper extremity (Modified Ashworth ≥ 3).\n* Significant sensory loss of the upper extremity (Upper Extremity sensory section of the Fugl-Meyer Assessment score \\\u003C 6).\n* Current requirement, or likely future requirement, of diathermy.\n* Current use of any other stimulation device, such as a pacemaker or other neurostimulator.\n* Pregnancy or plans to become pregnant or to breastfeed during the study period.\n* Participated in any other clinical trials within the preceding 3 months.\n* Not considered to be applicable by the investigator.","22 Years","79 Years",{"count":228,"type":22},[25],"The goal of this clinical trial is to investigate the efficacy and safety of vagus nerve stimulation (VNS) combined with rehabilitation in improving upper extremity motor function after spontaneous intracerebral hemorrhage (ICH).\n\nResearchers will evaluate the efficacy and safety of VNS by comparing the improvements of arm motor function post-ICH in the active VNS combined rehabilitation group with that in the sham VNS combined rehabilitation group (actual intensity 0 mA).\n\nParticipants in this study will undergo a surgical procedure to implant the VNS system and will subsequently recieve a 6 weeks in-clinic therapy, followed by an additional 6 weeks home exercise. During the final 6 weeks, participants will either recieve in-clinic therapy or maintain their home exercise, depending on their assigned group.",[532,533,534,535,536],"Spontaneous Intracerebral Hemorrhage","Motor Function","Upper Extremity Injury","Rehabilitation","Vagus Nerve Stimulation",[538,539,540,536,541,542,535],"Stroke","Hemorrhagic Stroke","Upper Extremity Paresis","Neuromodulation","Randomized Controlled Trial","2025-03-23",{"date":545,"type":38},"2025-03-26",{"date":262,"type":22},{"date":548,"type":22},"2027-12-30",{"name":44,"class":45},{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":556,"eligibilityCriteria":557,"healthyVolunteers":12,"sex":18,"minAge":558,"maxAge":4,"enrollmentInfo":559,"targetDuration":4,"studyType":23,"phases":561,"briefSummary":562,"conditions":563,"keywords":565,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":573,"completionDateStruct":575,"leadSponsor":576,"locationsCount":46},"100415226","safety-and-efficacy-of-stereotactic-aspiration-plus-urokinase-in-deep-intracerebral-hemorrhage-evacuation-100415226","NCT04686877","Safety and Efficacy of Stereotactic Aspiration Plus Urokinase in Deep Intracerebral Hemorrhage Evacuation","Safety and Efficacy of Stereotactic Aspiration Plus Urokinase in Deep Intracerebral Hemorrhage Evacuation: a Multicentral Randomized, Controlled, Open-label, Trial","STAPLE-dICH","Inclusion criteria:\n\n1. aged 40 years or older;\n2. the duration from onset to the baseline computed tomography angiography (CTA) scan was between 6 to 24 hours;\n3. patients with a spontaneous ICH in the deep brain parenchyma (≥1 cm from the cortical surface); with hematoma volume more than 25 ml (measured with the ABC\u002F2 method); without hydrocephalus caused by intraventricular hemorrhage; without cerebral herniation and the benefit of surgical treatment was unknown;\n4. The Glasgow Coma Scale (GCS) ranged from 9 to 15;\n5. patients with motor deficits;\n6. The modified Rankin Score (mRS) ranged from 0 to1 before onset.\n\nExclusion Criteria:\n\n1. ICH was caused by aneurysms, arteriovenous malformations, tumors, or trauma;\n2. patients had a history of intracerebral hemorrhage or ischemic cerebral infarction;\n3. patients had severe coagulation disorders with INR ≥ 1.5;\n4. patients had severe underlying diseases, which may affect the outcomes;\n5. pregnant and lactating patients;\n6. patients refused to sign the informed consent and receive follow-up.","40 Years",{"count":560,"type":22},400,[25],"This is a nationwide, multicenter, open-label, randomized controlled trial of early minimally invasive treatment for deep-seated spontaneous cerebral hemorrhage (dICH). The study consists of 2 steps: the first step is to conduct a dose climbing test to determine the safety and optimal dose of urokinase intra-hematoma irrigation after stereotactic aspiration; the second step is to validate whether stereotactic aspiration plus urokinase irrigation (the optimal dose determined in step one) is superior to conservative treatment in improving long-term outcomes (1 year) in early (within 24h) dICH patients.",[564],"Treatment of Spontaneous Intracerebral Hemorrhage",[566,567,568,542,569],"Deep-Seated Spontaneous Intracerebral Hemorrhage","Stereotactic Aspiration","Urokinase Irrigation","Long-term outcome","2025-02-08",{"date":572,"type":38},"2025-02-12",{"date":574,"type":38},"2021-01-31",{"date":401,"type":22},{"name":44,"class":45},{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":4,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":151,"enrollmentInfo":584,"targetDuration":4,"studyType":23,"phases":585,"briefSummary":586,"conditions":587,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":595,"locationsCount":46},"100576883","phase-2-clinical-study-of-envafolimab-combined-with-fruquintinib-and-chemotherapy-for-neoadjuvant-treatment-of-gastric-cancer-100576883","NCT06791083","Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer","Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer: a Single-arm, Open Clinical Study","Inclusion Criteria:\n\n1. Have fully understood the study and voluntarily signed the informed consent;\n2. Aged 18-75 years (including 18 and 75 years);\n3. Pathologically confirmed or potentially resectable locally advanced gastric\u002Fgastroesophageal junction adenocarcinoma (cT2-T4b, N+M0);\n4. If bone metastasis is suspected, a bone scan should be performed. If peritoneal metastasis is suspected, abdominal examination should be performed to rule out distant metastasis.\n5. At least 1 measurable lesion according to RECIST v1.1 criteria;\n6. United States Eastern Cancer Consortium (ECOG) Physical status score 0-1; BMI≥18;\n7. Expected survival ≥12 weeks;\n8. The functions of vital organs during the first 14 days of enrollment met the following requirements:\n\n   * Absolute neutrophil count ≥1.5×109\u002FL;\n   * Platelet ≥80×109\u002FL;\n   * Hemoglobin ≥90g\u002FL;\n   * Total bilirubin \\< 1.5 ULN; ALT and AST \\< 2.5 ULN (\\< 5 ULN in patients with liver metastasis);\n   * Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (CCr)≥60ml\u002Fmin;\n   * endogenous creatinine clearance \\> 50ml\u002Fmin;\n9. Female subjects of childbearing age or male subjects whose sexual partner is a female of childbearing age should take effective contraceptive measures during the whole treatment period and 6 months after the treatment period;\n10. Good compliance, cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Known HER2-positive patients;\n2. Participated in other drug clinical trials and received at least one drug therapy within 4 weeks prior to enrollment or received other systemic anti-tumor therapy, including chemotherapy, signal transduction inhibitors, immunotherapy, and other investigational drugs within 4 weeks prior to enrollment;\n3. Had other malignancies within 5 years prior to admission, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix;\n4. Receive live vaccine within 4 weeks prior to enrollment or possibly during the study period;\n5. Had active autoimmune disease or history of autoimmune disease within 4 weeks prior to enrollment;\n6. Previously received allogeneic bone marrow transplantation or organ transplantation;\n7. The patient has a current disease or condition that affects drug absorption, or the patient cannot take Fruquintinib orally;\n8. Subjects who are allergic to the investigational drug or any of its adjuncts;\n9. The investigator identified clinically significant electrolyte abnormalities;\n10. Hypertension that could not be controlled by drugs before enrollment was defined as: systolic blood pressure ≥150 mmHg and\u002For diastolic blood pressure ≥100 mmHg;\n11. Gastrointestinal diseases such as active ulcer of stomach and duodenum, ulcerative colitis, or active bleeding of unresectable tumors, or other conditions that may cause gastrointestinal bleeding or perforation as determined by researchers before enrollment;\n12. Patients with significant evidence or history of bleeding tendency within 3 months (bleeding \\>30 mL within 3 months, accompanied by hematemesis, stool, and blood in the stool), hemoptysis (\\>5 mL of fresh blood within 4 weeks), or thromboembolic events (including stroke events and\u002For transient ischemic attacks) within 12 months prior to admission;\n13. History of severe cardiovascular and cerebrovascular diseases:\n\n    * Cerebrovascular accident (excluding lacunar infarction, minor cerebral ischemia, or transient ischemic attack), myocardial infarction, unstable angina, and poorly controlled arrhythmias (including QTc interval ≥ 450ms for men and 470 ms for women) within 6 months prior to first administration of the study drug (QTc interval Fridericia) Formula calculation);\n    * New York Heart Association (NYHA) heart function Grade \\> II or left ventricular ejection fraction (LVEF) \\< 50%;\n14. Known human immunodeficiency virus (HIV) infection; A known history of clinically significant liver disease, including viral hepatitis \\[active HBV infection, i.e., positive HBV DNA (\\>1×104 copies \u002FmL or \\>2000 IU\u002Fml) must be excluded for a known hepatitis B virus (HBV) carrier; Known hepatitis C virus infection (HCV) and HCV RNA positive (\\>1×103 copies \u002FmL), or other hepatitis, cirrhosis\\];\n\n16\\. Women who are pregnant (positive pregnancy test before medication) or breastfeeding; 17. Two consecutive routine urine tests indicated urine protein ≥2+, and the urine protein volume \\>1.0g within 24 hours of reexamination; 18. Patients with ascites or pleural effusion with clinical symptoms; 19. CTCAE V5.0 grade 1 or higher toxicity due to any previous anticancer treatment that is not resolved, excluding oxaliplatin induced alopecia, lymphocytopenia, and neurotoxicity ≤ grade 2; 20.Patients considered inappropriate for inclusion in this study.",{"count":372,"type":22},[132],"To observe and evaluate the neoadjuvant treatment of Envafolimab combined with Fruquintinib and chemotherapy for locally advanced gastric\u002Fgastroesophageal junction carcinoma",[588],"Gastric Cancer","2025-01-19",{"date":591,"type":38},"2025-01-24",{"date":593,"type":38},"2024-06-20",{"date":474,"type":22},{"name":44,"class":45},{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":23,"phases":605,"briefSummary":606,"conditions":607,"keywords":611,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":624,"locationsCount":46},"100534054","multi-center-clinical-study-on-hemoperfusion-of-kha80-100534054","NCT06233838","Multi-center Clinical Study on Hemoperfusion of KHA80","Prospective, Multicenter, Randomized, Open Label Study on the Efficacy and Safety of Comparison of KHA80 Blood Perfusion Combined With Hemodialysis and Conventional Hemodialysis in Clearing IL-6, β2-MG and PTH in Maintenance Hemodialysis Patients","Inclusion Criteria:\n\n1. Age ≥18 years old, regardless of sex;\n2. According to the 2012 KDIGO guidelines, it was diagnosed as CKD5 (EGFR ≦ 15ml\u002F(min ˙ 1.73m2));\n3. receive regular hemodialysis (including hemodialysis filtration) for 4 hours twice a week for ≧3 months;\n4. blood β 2-mg ≥ 30 mg\u002FL and\u002For PTH ≥ 600 pg\u002FmL and\u002For IL-6 ≥ 16.2 pg\u002FmL;\n5. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. Those who are known to have allergic reactions, contraindications or intolerance to the materials of dialyzers and hemoperfutors;\n2. Patients with severe bleeding tendency and active bleeding, or with definite coagulation dysfunction, with a platelet count of \\\u003C 60× 109\u002FL;\n3. Hemodialysis blood flow \\\u003C 200 ml\u002Fmin.\n4. Kt\u002FV\\\u003C1.2；\n5. Serum albumin \\\u003C 30g\u002FL;\n6. Parathyroid resection within one year;\n7. people with low blood pressure and severe cardiopulmonary insufficiency;\n8. lactating or pregnant women or those who plan to be pregnant within one year;\n9. infection, history of malignant tumor, active stage of rheumatic immune disease;\n10. Patients whose life expectancy is less than one year;\n11. Other clinical researchers are currently or recently (within 30 days);\n12. According to the researcher's judgment, the patient has other unsuitable conditions.",{"count":604,"type":22},394,[25],"To evaluate the decreasing rate of blood IL-6, β2-MG and PTH in maintenance hemodialysis patients in the 52nd week compared with routine hemodialysis.",[608,609,610],"Uremia","Uremic Osteodystrophy","Dialysis Related Complication",[612,613,614,615,616],"KHA80","Maintenance hemodialysis","IL-6","β2-MG","PTH","2025-01-10",{"date":619,"type":38},"2025-01-14",{"date":621,"type":22},"2025-01-13",{"date":623,"type":22},"2027-05-31",{"name":44,"class":45},""]